A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 111 participants.

Also called NCT03311724

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 111 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03311724
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03311724. Randomized; double masking; primary purpose treatment. Start 2017-10-19 (actual); primary completion 2018-04-24 (actual). Results posted on 2021-05-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03311724
Content hash
1d61b6d40f6fc1dc77827c6ad259b9deeb0667c721793d3cb7517fb7c1b77b2b